Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

[1]  A. Capucci,et al.  Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT , 2017, European heart journal.

[2]  Paul L. Hess,et al.  The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review , 2017, JAMA cardiology.

[3]  B. Maron,et al.  Shared decision-making in HCM , 2017, Nature Reviews Cardiology.

[4]  S. Willems,et al.  High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device , 2016, Journal of cardiovascular electrophysiology.

[5]  J. Voss,et al.  Silent AF and Hypertrophic Stroke Risk: More Data, More Monitoring , 2016, Journal of cardiovascular electrophysiology.

[6]  N. Hagiwara,et al.  Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation , 2016, Stroke.

[7]  R. Omar,et al.  Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA) , 2015, European journal of heart failure.

[8]  J. Halperin,et al.  Device-detected atrial fibrillation: what to do with asymptomatic patients? , 2015, Journal of the American College of Cardiology.

[9]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[10]  B. Gersh,et al.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High‐Risk Population , 2014, Journal of the American Heart Association.

[11]  B. Maron,et al.  Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. , 2014, The American journal of cardiology.

[12]  Paul J. Wang,et al.  Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy , 2013, Heart.

[13]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[14]  T. Kubo,et al.  Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[15]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[16]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[17]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[18]  D. Theuns,et al.  Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.